EU "needs stockpile of avian flu drugs"

30 January 2006

Austria's Health Minister, Maria Rauch-Kallat, has reop-ened the issue of creating a common stockpile of antivirals to combat avian influenza, after the project had been scrapped earlier this month, on the grounds that the risk of an outbreak in Europe was insufficient. With recent reports of avian flu gathering pace in Turkey, the possibility of the disease spreading across Europe has grown. A meeting of the European Union's health ministers is scheduled for April, at which Mrs Rauch-Kallat (as chairman, under the EU's rotating presidency) will propose the idea of a common stockpile.

EC can't coordinate pandemic response

Mrs Rauch-Kallat also believes that the stockpile of anti-virals should be handled by the World Health Organization, rather than the European Commission, on the grounds that the latter has no experience of dealing with a health crisis of the potential magnitude of bird flu. The issue is bound to raise controversy, both in terms of whether the EC or WHO should manage any stockpile, as well as the idea that national governments might have to coordinate their strategies for combatting a pandemic.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight